Celldex Therapeutics (CLDX) vs Achieve Life Sciences (QUIT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Celldex Therapeutics is the larger company by market cap ($2.15 billion vs $573.2 million), about 3.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLDX | QUIT |
|---|---|---|
| Share price | $27.42 | $5.56 |
| Market cap | $2.15B | $573.25M |
| 1-day change | -1.93% | -5.28% |
| YTD return | +0.96% | — |
| 1-year return | +5.79% | — |
| 5-year return | -30.78% | — |
| EPS (TTM) | $-4.29 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.54M | — |
| Revenue growth (YoY) | -77.99% | — |
| Net income (latest FY) | $-258.76M | $-54.65M |
| Gross margin | 87.06% | — |
| Operating margin | -18599.81% | — |
| Net margin | -16748.03% | — |
| 52-week high | $45.14 | $8.64 |
| 52-week low | $22.33 | $2.62 |
| Distance from 52-week high | -39.26% | -35.65% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +133.41% | +162.23% |
| Average volume | 1.33M | 1.38M |
| Shares outstanding | 78.55M | 103.10M |
| Employees | 198 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Celldex Therapeutics is about 3.8 times larger than Achieve Life Sciences by market value ($2.15B vs $573.25M).
About Celldex Therapeutics
CLDX stock →Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 198 employees
About Achieve Life Sciences
QUIT stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
CLDX vs QUIT FAQ
Which is bigger, Celldex Therapeutics or Achieve Life Sciences?
Celldex Therapeutics (CLDX) is larger, with a market capitalization of $2.15B compared with $573.25M for Achieve Life Sciences (QUIT).
Are Celldex Therapeutics and Achieve Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.